Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of June 2015, with a report date of June 8, 2015. The filing serves as an English translation of an immediate report submitted to the Tel-Aviv Stock Exchange and the Israeli Securities Authority regarding changes in significant shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholder ownership changes rather than a financial performance report.
Material Changes
The filing details significant increases in shareholdings by IBI Investment House Ltd. in two capacities:
- As Market Maker: Holdings increased by 7,970 shares, rising from a previous balance of 910 shares. The maximum holding rate during the period was 0.02%.
- As Management Company of Mutual Investment Trust Funds: Holdings increased by 2,683,659 shares, rising from a previous balance of 6,607,098 shares. The holding rate ranged from a minimum of 5.84% to a maximum of 12.17% during the reported period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is strictly limited to reporting the specific shareholding changes noted above.
Investor Verification Checklist
- Verify the total outstanding share count of BiondVax Pharmaceuticals Ltd. to confirm the accuracy of the reported 12.17% maximum holding rate.
- Confirm whether the increase in holdings by IBI Investment House Ltd. represents a strategic investment or routine market-making activity.
- Check subsequent filings to determine if the 12.17% holding threshold triggered any additional disclosure obligations under Israeli or U.S. regulations.